上海葆隆生物科技有限公司
Shanghai Baolong Biotech Co.,ltd

Quality Consistency Evaluation ,launched by CFDA, focus on consistency of composition and clinical efficiency between the test and reference products. At the first stage, the scope is limited to evaluate oral solid products, which were approved prior to issuance of new version of “Provisions for Drug Registration”(effective in 2007). If the quality of test product is not consistent with the reference product, the formulation and process should be re-developed to bridge the gap.